RenovoRx

During the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, RenovoRx CEO, Shaun Bagai, will highlight progress in the pivotal Phase III TIGeR-PaC clinical trial, which is evaluating intra-arterial gemcitabine delivered via RenovoCath® in . Enrollment is expected to be completed by the end of June 2026 and final data anticipated in mid-to-late 2027. Learn more: https://bit.ly/4ertmCT

Rare Cancer News highlighted RenovoRx’s recent FDA Orphan Drug Designation for oxaliplatin in the treatment of pancreatic cancer. This marks the company’s third orphan drug designation and further advances RenovoRx’s oncology pipeline while providing seven years of market exclusivity. Read more: https://bit.ly/4vbvTrF

Dr. Jonathan Kessler, Chief of Interventional Radiology at City of Hope, recently joined the Living Hope Podcast to discuss his work with a multidisciplinary oncology team treating and the need for new treatment options. He highlighted the potential of RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to enhance local drug-delivery in difficult-to-treat tumors while potentially reducing the toxicities associated with systemic chemotherapy.

Listen to the episode here: https://bit.ly/4veDHJy

RenovoCath is cleared by FDA for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial study conducted under an IND.

Ramtin Agah, MD, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder comments on the recently published peer-reviewed case study from researchers at Moffitt Cancer Center supporting the procedural flexibility and targeted delivery capabilities of our TAMP platform enabled by RenovoCath. Read more: https://bit.ly/4owgpft

A recently published peer-reviewed case study from researchers at Moffitt Cancer Center found PET-CT imaging, rather than CT alone, showed a meaningful reduction in tumor metabolic activity after treatment, suggesting that PET may improve monitoring of therapeutic response following treatment delivered via TAMP. Find details: https://bit.ly/4owgpft

RenovoRx announced the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports. The case study suggests the TAMP procedure with RenovoCath® may optimize delivery of intra-arterial gemcitabine directly near a tumor in a patient with , rather than through systemic IV administration. PET-CT imaging also showed a meaningful drop in tumor metabolic activity after treatment, suggesting PET may better monitor response following TAMP. Learn more: https://bit.ly/4owgpft

RenovoRx Chief Clinical Officer, Leesa Gentry, will participate in a panel at San Francisco tomorrow, June 11th at 10:30–11:15 AM PT, on “Beyond the AI Hype: What Actually Changes in Clinical Development.” The discussion will focus on practical AI adoption in clinical research, including improved efficiency, earlier risk detection, governance, and responsible implementation in regulated environments. Learn more: https://bit.ly/49TTbtF

Fox News spotlighted RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) platform, which uses the RenovoCath® device to enable targeted delivery of therapy in difficult-to-treat tumors, like . TAMP is designed to localize therapy delivery while potentially reducing systemic exposure and improving patient outcomes. Read more: https://bit.ly/4dWwAix

RenovoCath is cleared by FDA for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial study conducted under an IND.

New Cancer Tech Sends Chemo Straight To Tumors A targeted drug-delivery device may help some pancreatic cancer patients get chemotherapy with fewer body-wide side effects.

Our CEO, Shaun Bagai, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on Tuesday, June 23rd at 12:30 P.M. ET. Mr. Bagai will discuss RenovoRx’s record first quarter 2026 revenue, driven by growing demand for RenovoCath® as a standalone drug-delivery device. He will also highlight RenovoCath’s accelerating adoption at high-volume cancer centers and the expanding base of repeat orders. For details: https://bit.ly/4uSjNDT

Leesa Gentry, Chief Clinical Officer of RenovoRx, comments on the Company’s recently granted FDA Orphan Drug Designation to oxaliplatin for the treatment of pancreatic cancer. This designation further supports the versatility of RenovoRx's novel approach to delivering multiple therapeutic agents directly near the tumor site. https://bit.ly/3RBqdsf